Semaglutide for Faster Healing of Diabetic Foot Ulcers
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Skin clinical trials.
This study tests whether a diabetes medication called semaglutide can help foot ulcers heal faster in people with type 2 diabetes. If it works, it could offer a new treatment option for a common and serious diabetes complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes diagnosed at least 6 months ago
- You have an open foot ulcer (wound) below the ankle, between 5 and 3,000 square millimeters after cleaning
- You are age 18–90 and able to visit the clinic weekly
- You have not used GLP-1 drugs (like Ozempic, Trulicity) in the last 3 months
- You have not had a heart attack, stroke, or major leg surgery in the last 3 months
- You are not pregnant, breast-feeding, or planning pregnancy (or using effective birth control)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This Phase 2 study tests whether a semaglutide injection given under the skin soon after an acute ischemic stroke can improve recovery. It may help reduce disability, especially if treatment starts within about 4.5 hours of symptom onset.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
Hear when a new Foot Ulcer Due to Type 2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.